Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: Extending the potential of broadly cross-protecting epitopes

被引:21
作者
Wibowo, Nani [1 ]
Hughes, Fiona K. [1 ]
Fairmaid, Emily J. [2 ]
Lua, Linda H. L. [3 ]
Brown, Lorena E. [2 ]
Middelberg, Anton P. J. [1 ]
机构
[1] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Ctr Biomol Engn, St Lucia, Qld 4072, Australia
[2] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia
[3] Univ Queensland, Prot Express Facil, St Lucia, Qld 4072, Australia
关键词
Capsomere; E; coli; M2e; Rapid manufacture; Vaccine; EXTRACELLULAR DOMAIN; A VIRUSES; ESCHERICHIA-COLI; PARTICLE VACCINE; PROTEIN; ANTIBODY; INFECTION; IMMUNITY; DENSITY; CARRIER;
D O I
10.1016/j.vaccine.2014.04.062
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Influenza A viruses drift and shift, emerging as antigenically distinct strains that lead to epidemics and pandemics of varying severity. Even epitopes associated with broad cross-protection against different strains, such as the ectodomain of matrix protein 2 (M2e), mutate unpredictably. Vaccine protective efficacy is only ensured when the emerging virus lies within the vaccine's cross-protective domain, which is poorly defined in most situations. When virus emerges outside this domain it is essential to rapidly re-engineer the vaccine and hence re-center the cross-protective domain on the new virus. This approach of vaccine re-engineering in response to virus change is the cornerstone of the current influenza control system, based on annual prediction and/or pandemic reaction. This system could become more responsive, and perhaps preventative, if its speed could be improved. Here, we demonstrate vaccine efficacy of a rapidly manufacturable modular capsomere presenting the broadly cross-protecting M2e epitope from influenza. M2e inserted into a viral capsomere at the DNA level was expressed in Escherichia coli as a fusion protein (Wibowo et al., 2013). Immunization of mice with this modular capsomere adjuvanted with conventional aluminum hydroxide induced high (more than 10(5) endpoint titer) levels of M2e-specific antibodies that reduced disease severity and viral load in the lungs of challenged mice. The combination of rapid manufacturability of modular capsomere presented in this study, and the established cross-protective efficacy of M2e, allow rapid matching of vaccine to the circulating virus and hence rapid re-centering of the vaccine's cross-protective domain onto the virus. This approach synergizes the discussed benefits of broadly cross-protecting epitopes with rapid scale-up vaccine manufacture using microbial cell factories. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3651 / 3655
页数:5
相关论文
共 29 条
[1]   Influenza vaccine effectiveness among adult patients in a University of Lyon hospital (2004-2009) [J].
Amour, Selilah ;
Voirin, Nicolas ;
Regis, Corinne ;
Bouscambert-Duchamp, Maude ;
Comte, Brigitte ;
Coppere, Brigitte ;
Pires-Cronenberger, Silene ;
Lina, Bruno ;
Vanhems, Philippe .
VACCINE, 2012, 30 (05) :821-824
[2]   Increased Immunogenicity and Protective Efficacy of Influenza M2e Fused to a Tetramerizing Protein [J].
Andersson, Anne-Marie Carola ;
Hakansson, Kjell O. ;
Jensen, Benjamin Anderschou Holbech ;
Christensen, Dennis ;
Andersen, Peter ;
Thomsen, Allan Randrup ;
Christensen, Jan Pravsgaard .
PLOS ONE, 2012, 7 (10)
[3]   Influenza vaccine: The challenge of antigenic drift [J].
Carrat, F. ;
Flahault, A. .
VACCINE, 2007, 25 (39-40) :6852-6862
[4]   Production of recombinant proteins by high cell density culture of Escherichia coli [J].
Choi, JH ;
Keum, KC ;
Lee, SY .
CHEMICAL ENGINEERING SCIENCE, 2006, 61 (03) :876-885
[5]   High-level expression of soluble viral structural protein in Escherichia coli [J].
Chuan, Yap P. ;
Lua, Linda H. L. ;
Middelberg, Anton P. J. .
JOURNAL OF BIOTECHNOLOGY, 2008, 134 (1-2) :64-71
[6]   Effects of Pre-Existing Anti-Carrier Immunity and Antigenic Element Multiplicity on Efficacy of a Modular Virus-Like Particle Vaccine [J].
Chuan, Yap P. ;
Rivera-Hernandez, Tania ;
Wibowo, Nani ;
Connors, Natalie K. ;
Wu, Yang ;
Hughes, Fiona K. ;
Lua, Linda H. L. ;
Middelberg, Anton P. J. .
BIOTECHNOLOGY AND BIOENGINEERING, 2013, 110 (09) :2343-2351
[7]   Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies [J].
De Filette, Marina ;
Martens, Wouter ;
Smet, Anouk ;
Schotsaert, Michael ;
Birkett, Ashley ;
Londono-Arcila, Patricia ;
Fiers, Walter ;
Saelens, Xavier .
VACCINE, 2008, 26 (51) :6503-6507
[8]   Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate Protection [J].
El Bakkouri, Karim ;
Descamps, Francis ;
De Filette, Marina ;
Smet, Anouk ;
Festjens, Els ;
Birkett, Ashley ;
Van Rooijen, Nico ;
Verbeek, Sjef ;
Fiers, Walter ;
Saelens, Xavier .
JOURNAL OF IMMUNOLOGY, 2011, 186 (02) :1022-1031
[9]   Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines [J].
Ernst, William A. ;
Kim, Hyung J. ;
Tumpey, Terrence M. ;
Jansen, Airan D. A. ;
Tai, Wendy ;
Cramer, Donald V. ;
Adler-Moore, Jill P. ;
Fujii, Gary .
VACCINE, 2006, 24 (24) :5158-5168
[10]   Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys [J].
Fan, JA ;
Liang, XP ;
Horton, MS ;
Perry, HC ;
Citron, MP ;
Heidecker, GJ ;
Fu, TM ;
Joyce, J ;
Przysiecki, CT ;
Keller, PM ;
Garsky, VM ;
Ionescu, R ;
Rippeon, Y ;
Shi, L ;
Chastain, MA ;
Condra, JH ;
Davies, ME ;
Liao, J ;
Emini, EA ;
Shiver, JW .
VACCINE, 2004, 22 (23-24) :2993-3003